Hardman & Co Research on International Biotechnology Trust (IBT): Industry M&A remains a key driver
Hardman Co Research
Hardman Co Research on International Biotechnology Trust (IBT): Industry M remains a key driver
10-Jul-2023 / 10:40 GMT/BST
The issuer is solely responsible for the content of this announcement.
Hardman Co Research on International Biotechnology Trust (IBT):
Industry M remains a key driver
IBT was established in 1994 to provide institutional and retail investors with the opportunity to participate in global biotechnology and life science companies, from venture-stage early drug discovery via venture capital funds (SV Health Investors) through to global, multinational biotechnology companies. The trust’s main aim is to generate capital growth, while minimising risk, through a diversified portfolio and an experienced investment team. Over the past five years, IBT’s NAV per share has increased 37%, while the share price has risen 36% in the same period – differentiated returns are generally due to changes in the share price discount.
Please click on the link below for the full report:
https://hardmanandco.com/research/corporate-research/industry-ma-remains-a-key-driver/
If you are interested in meeting the company, you can register your interest by clicking on the above link
To contact us:
Hardman Co
1 Frederick’s Place
London
EC2R 8AE
Follow us on Twitter @HardmanandCo
Contact:
Martin Hall
+44(0)203 693 7075
Hardman Co Research can still be accessed for free after MiFID II. Please click here to read the statement.
About Hardman Co: Hardman Research Ltd, trading as Hardman Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259. Attention is drawn to the important disclaimers at the end of the report.
Dissemination of a CORPORATE NEWS, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.
1676289 10-Jul-2023